A survey of approximately 4,000 questionnaires completed by parents of autistic children provided ratings on a variety of treatments and interventions. Among the biomedical treatments, the use of high-dosage vitamin B6 and magnesium (n = 318) received the highest ratings, with 8.5 parents reporting behavioral improvement to every one reporting behavioral worsening. Deanol (n = 121) was next most highly rated, with 1.8 parents reporting improvement to each one reporting worsening. Fenfluramine (n = 104) was third, with a ratio of 1.5:1. Thioridazine hydrochloride (Mellaril), by far the most often used drug on the list (n = 724), was fourth with a helped-worsened ratio of 1.4:1. The research literature on the use of vitamin B6-magnesium is briefly reviewed, and mention is made of recent findings regarding high-dosage folic acid in autism and biotin in Rett syndrome. (J Child Neurol 1988;3(Suppl):S68-S72).
Get full access to this article
View all access options for this article.
References
1.
Geller E., Ritvo E., Freeman BJ, et al: Preliminary observations on the effect of fenfluramine on blood serontonin and symptoms in three autistic boys. N Eng L Med1982;3:165-168.
2.
Ritvo E., Freeman BJ, Geller E., et al: Study of fenfluramine in outpatients with the syndrome of autism . J Pediatr1984 ;5 :823-828.
3.
Gualtieri T. : Fenfluramine and autism: careful reappraisal is in order. J Pediatr1986;108:418-419.
4.
Farber JM: Fenfluramine and autism. Dev Med Child Neurol1986;28:817-818.
5.
Rimland B.: Infantile Autism: The Syndrome and Its Implications for a Neural Theory of Behavior. New York, Prentice-Hall , 1964.
6.
Rimland B.: Megavitamin B6 and magnesium in the treatment of autistic children and adolescents , in Schopler E, Mesibov GB (eds): Neurobiological Issues in Autism. New York, Plenum Press, 1987, pp 389-405.
7.
Heeley AG, Roberts GE: A study of tryptophan metabolism in psychotic children. Dev Med Child Neuro1966;3:708-718.
8.
Bonisch VE: Erfahrungen mit Pyrithioxin bei hirngeschädigten kindern mit autistischen Syndrom. Prax Kinderpsychol Kinderpsychiatr1968;8:308-310.
9.
Rimland B.: High dosage levels of certain vitamins in the treatment of children with severe mental disorders, in Hawkins D , Pauling L (eds): Orthomolecular Psychiatry . San Francisco, WH Freeman , 1973, pp 513-539.
10.
Rimland B.: An orthomolecular study of psychotic children. Orthomolecular Psychiatry1974;3:371-377.
11.
Rimland B., Callaway E., Dreyfus P.: The effects of high doses of vitamin B6 on autistic children: A double-blind crossover study. Am J Psychiatry1978;135:472-475.
12.
Barthelemy C., Garreau B., Leddet I., et al: Behavioral and biological effects of oral magnesium, vitamin B6, and combined magnesium-B6 administration in autistic children. Magnesium Bull1981; 3:150-153.
13.
Barthelemy C., Garreau B., Leddet I., et al: Intérêt des échelles de comportement et des dosages de l' acide homovanillique urinaire pour le contrôle des effects d'un traitement associant vitamine B6 et magnésium chez des enfants ayant un comportement autistique. Neuropsychiatr Enfance Adolesc1983;31:289-301.
14.
Jonas C., Etienne T., Barthelemy C., et al: Intérêt clinique et biochimique de l'association vitamine B6 + magnesium dans le traitement de I'autisme résiduel a l'âge adulte. Therapie1984;39: 661-669.
15.
Lelord G., Muh JP, Barthelemy C., et al: Effects of pyridoxine and magnesium on autistic symptoms-initial observations. J Autism Dev Disord1981;11:219-230.
16.
Martineau J. , Garreau B., Barthelemy C., et al: Comparative effects of oral B6, B6-Mg, and Mg administration on evoked potentials conditioning in autistic children , in Rothenberger A (ed): Proceedings: Symposium on Event-Related Potentials in Children. Essen, West Germany, June 11-13, 1982. Amsterdam , Elsevier Biomedical Press, 1982 , pp 411-416.
17.
Martineau J. , Barthelemy C., Garreau B., et al: Vitamin B6, magnesium and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry1985;20:467-468.
18.
Martineau J. , Barthelemy C., Lelord G.: Long-term effects of combined vitamin B6-magnesium administration in an autistic child. Biol Psychiatry1986;21:511-518.
19.
Lelord G., Barthelemy C., Martineau N., et al: Clinical and biological effects of vitamin B6 + magnesium in autistic subjects, in Leklem J, Reynolds R (eds): Vitamin B6 Responsive Disorders in Humans. New York, Alan R Liss , 1988, pp 329-356.
20.
Gualtieri CT, van Bourgondien ME, Hartz C., et al: A pilot study of pyridoxine treatment in autistic children. Presented at American Psychiatric Association meeting, New Orleans, May, 1981.
21.
Ellman G.: Pyridoxine effectiveness on autistic patients at Sonoma State Hospital . Presented at Research Conference on Autism, San Diego, Nov 1, 1981.
22.
Rosenberg LE : Vitamin-dependent genetic disease. Hosp Pract1970;(july 15):59-66.
23.
American Academy of Pediatrics: Vitamin B6 requirements in man. Pediatrics1966;38:1068-1076.
24.
Schaumburg H., Kaplan J., Windebank A., et al: Sensory neuropathy from pyridoxine abuse. N Engl J Med1983;309:445-448.
25.
Institute for Child Behavior Research: Folic acid for fragile X: treatment results mixed. Autism Res Rev Int1987;1:6.
26.
Institute for Child Behavior Research: Folic acid effective?Autism Res Rev Int1987 ;4:2.
27.
Institute for Child Behavior Research: Syndrome linked to metabolic defect. Autism Res Rev Int1987;2:7.
28.
Form Letter Regarding High Dosage Vitamin B6 and Magnesium Therapy for Autism and Related Disorders, Publication No. 39, October 1987. Institute for Child Behavior Research, 4182 Adams Ave, San Diego, CA92116.
